AI-generated summary
The authors report a randomized, double-blind trial of photobiomodulation or sham laser in adults with blood cancers receiving high-dose methotrexate, finding that active treatment was associated with less ulcerative oral mucositis at 96 hours. They also report that salivary methotrexate, but not serum levels, was independently associated with mucositis severity, suggesting it as a possible biomarker.
- Participants
- 53
- Who or what was studied
- Adults with hematological malignancies undergoing a first cycle of high-dose methotrexate at a tertiary cancer center in Brazil
- Limits stated in the abstract
- The abstract describes a phase II trial and does not state its sample size per group analysis limits, long-term follow-up, or wavelength parameters, and the salivary biomarker finding is described as promising rather than confirmed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Objective
To evaluate the efficacy of prophylactic photobiomodulation therapy (PBMT) in preventing oral mucositis (OM) and to assess serum and salivary methotrexate (MTX) levels as predictors of OM in adults receiving high-dose methotrexate (HD-MTX).
Methods
This phase II randomized, double-blind, placebo-controlled trial enrolled adults with hematological malignancies undergoing a first HD-MTX cycle at a tertiary cancer center in Brazil. Participants were randomized to PBMT or sham laser therapy, administered daily until MTX clearance or for up to five sessions. OM was assessed for 9 days using WHO criteria. Serum and salivary MTX concentrations were measured at 24, 48, and 72 h post-infusion, along with urinary pH and serum creatinine.
Results
Fifty-three patients were randomized (PBMT n = 26; placebo n = 27). PBMT significantly reduced ulcerative OM (grade ≥ 2) at 96 h (11.5% vs. 51.9%), yielding a 77.7% relative risk reduction and a number needed to treat of 2 (p < 0.01). Placebo recipients had an 8.97-fold higher odds of severe OM. Serum MTX was not associated with OM, whereas salivary MTX increased disproportionately over time and independently correlated with OM severity.
Conclusions
PBMT significantly reduced OM incidence and severity in adults receiving HD-MTX. Salivary MTX is a promising non-invasive biomarker for OM risk.
Trial Registration
Trial was prospectively registered in the Brazilian Registry of Clinical Trials (ReBec, No. 12218).
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Oral mucositis, Photobiomodulation, Placebo-controlled, Trial registration, Biomarker, GRADE, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.